Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biolipox, Inflazyme deal

Biolipox will acquire IZP's leukocyte selective anti-inflammatory drugs (LSAID) and phosphodiesterase-4 (PDE-4) inhibitor programs and its Prodaptin tethering technology that can increase a drug's

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE